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Abstract
Purpose: To assess the frequency of chronic kidney disease (CKD), define the associated demographics, and evaluate its
association with use of evidence-based drug therapy in a contemporary global study of patients with stable coronary artery
disease.
Methods: 22,272 patients from the ProspeCtive observational LongitudinAl RegIstry oF patients with stable coronary arterY
disease (CLARIFY) were included. Baseline estimated glomerular filtration rate (eGFR) was calculated (CKD-Epidemiology
Collaboration formula) and patients categorised according to CKD stage: .89, 60–89, 45–59 and ,45 mL/min/1.73 m2.
Results: Mean (SD) age was 63.9610.4 years, 77.3% were male, 61.8% had a history of myocardial infarction, 71.9%
hypertension, 30.4% diabetes and 75.4% dyslipidaemia. Chronic kidney disease (eGFR,60 mL/min/1.73 m2) was seen in
22.1% of the cohort (6.9% with eGFR,45 mL/min/1.73 m2); lower eGFR was associated with increasing age, female sex,
cardiovascular risk factors, overt vascular disease, other comorbidities and higher systolic but lower diastolic blood pressure.
High use of secondary prevention was seen across all CKD stages (overall 93.4% lipid-lowering drugs, 95.3% antiplatelets,
75.9% beta-blockers). The proportion of patients taking statins was lower in patients with CKD. Antiplatelet use was
significantly lower in patients with CKD whereas oral anticoagulant use was higher. Angiotensin-converting enzyme
inhibitor use was lower (52.0% overall) and inversely related to declining eGFR, whereas angiotensin-receptor blockers were
more frequently prescribed in patients with reduced eGFR.
Conclusions: Chronic kidney disease is common in patients with stable coronary artery disease and is associated with
comorbidities. Whilst use of individual evidence-based medications for secondary prevention was high across all CKD
categories, there remains an opportunity to improve the proportion who take all three classes of preventive therapies.
Angiotensin-converting enzyme inhibitors were used less frequently in lower eGRF categories. Surprisingly the reverse was
seen for angiotensin-receptor blockers. Further evaluation is required to fully understand these associations. The CLARIFY
(ProspeCtive observational LongitudinAl RegIstry oF patients with stable coronary arterY disease) Registry is registered in
the ISRCTN registry of clinical trials with the number ISRCTN43070564. http://www.controlled-trials.com/ISRCTN43070564.
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Introduction
Chronic kidney disease (CKD) is a powerful independent
predictor of adverse prognosis following myocardial infarction
(MI) [1,2] or coronary revascularization [3,4]. A recent study has
shown that post MI the presence of CKD (defined as estimated
glomerular filtration rate, eGFR, ,60 mL/min/1.73 m2) was a
stronger predictor of all-cause mortality than either a history of MI
or diabetes [2]. Compared with a reference population without a
history of MI, CKD or diabetes, the presence of CKD was
associated with a 3.6-fold unadjusted relative rate of all-cause
mortality; the respective rates for patients with history of MI or
diabetes were 2.7 and 1.9.
A number of plausible reasons might explain this link. CKD
may merely represent a bystander marker of advancing age and
comorbidities. Alternatively pathophysiological derangements in
patients with CKD such as activation of the renin-angiotensin-
aldosterone systems, inflammatory immune activation or disor-
dered calcium-phosphate metabolism might contribute to cardio-
vascular disease progression or expression [5,6]. Underutilization
of evidence-based treatments in patients with CKD and coronary
artery disease (CAD) may also play a role. Historical data have
suggested that despite major advances in secondary prevention
following MI, patients with CKD are less commonly prescribed
prognostically beneficial drugs. For example, data from 14,527
patients with acute MI complicated by heart failure (Valsartan
in Acute Myocardial Infarction Trial) showed that declining
eGFR was associated with increased risk of death and non-
fatal cardiovascular outcomes [1]. Whilst patients with eGFR
,45 mL/min/1.73 m2 were at highest risk of events, the use of
aspirin, beta-blockers, statins or coronary revascularization was
lowest in this group. A retrospective cohort study of Medicare
patients with acute MI showed that those with CKD stage 4
(eGFR 15–29 mL/min/1.73 m2) were infrequently prescribed
aspirin with beta-blockers (27.1%) and fewer than one in 10 were
prescribed the combination of aspirin, beta-blockers and angio-
tensin-converting enzyme (ACE) inhibitors [7]. Similar data were
found in a single-centre prospective study for patients discharged
after acute MI [8].
Patients with CKD and CAD are at higher absolute risk of
adverse events and many are therefore likely to derive marked
benefit from secondary prevention. Identifying and subsequently
rectifying deficiencies of care in such patients has the potential to
impact positively on outcomes. The aims of the current study were
to assess the frequency of CKD, define the associated demograph-
ics, and evaluate the impact of CKD on medical therapy in a large
contemporary global study of patients with stable CAD: the
ProspeCtive observational LongitudinAl RegIstry oF patients with
stable coronary arterY disease (CLARIFY) [9]. We hypothesized
that patients with advanced CKD would receive suboptimal
secondary prevention compared to patients with preserved renal
function. This unique, contemporary cohort study has enabled us
to evaluate these objectives in detail.
Methods
Ethics Statement
The study was conducted in accordance with the principles in
the Declaration of Helsinki and local ethical approval was
obtained as necessary in all countries prior to recruitment. All
patients gave written informed consent.
Study Design
CLARIFY is an ongoing international, prospective, observa-
tional, longitudinal cohort study in outpatients with stable CAD.
The study rationale and methods have been published elsewhere
(further information can be found online at www.clarify-registry.
com) [9,10]. Briefly, the registry was designed to collect data on
the current status of outpatients with stable CAD, including their
demographic characteristics, clinical profiles, therapeutic strate-
gies, and outcomes. More than 33,000 patients were enrolled in 45
countries in Africa, Asia, Australia, Europe, the Middle East, and
North, Central and South America. A detailed list of countries,
sites, and investigators has already been published [10]. Patients
are followed up for 5 years with data collected prospectively at
annual visits, and interim phone calls every 6 months. Patients are
treated according to usual clinical practice at each institution, with
no specific tests or therapies defined in the study protocol. The
current study relates to data collected at baseline assessment.
Study Design and Patients
The 2,884 participating physicians were selected on the basis of
their geographic distribution; each was requested to recruit 10–15
consecutive stable outpatients with CAD to meet a predefined
country target of 25 patients per million inhabitants (range 12.5–
50) and obtain an epidemiologically representative population in
each country. Eligible patients had stable CAD proven by a history
of at least one of the following: documented MI (.3 months
before enrolment); angiographic demonstration of coronary
stenosis .50%; chest pain with evidence of myocardial ischaemia
(stress electrocardiogram, stress echocardiograph or myocardial
perfusion imaging); or coronary artery bypass graft (CABG) or
percutaneous coronary intervention (PCI) performed .3 months
before enrolment. These criteria were not mutually exclusive.
Exclusion criteria included hospital admission for cardiovascular
reasons (including revascularization) in the past 3 months, planned
revascularization, or conditions hampering participation for the
5-year follow-up, such as limited cooperation, inability to provide
informed consent, serious non-cardiovascular disease or conditions
interfering with life expectancy (e.g. cancer, drug abuse) or severe
other cardiovascular disease (e.g. advanced heart failure, severe
valve disease, history of valve repair/replacement). CKD per se
was not an exclusion criterion. To ensure that the study population
was representative of stable CAD outpatients, recruitment of sites
and subjects was based on predefined selection of physicians
(cardiologists, as well as office-based primary care physicians and
physicians based in hospitals with outpatient clinics) by national
coordinators, using the best available epidemiological data in each
country reflecting the burden of CAD; this was done in an attempt
to provide a distribution of physicians across regions and locations
(i.e. urban, suburban, or rural areas) mimicking the epidemiolog-
ical patterns in each country. In each practice, patient enrolment
was restricted over a brief period to achieve near consecutive
patient enrolment in order to avoid selection bias. The first patient
was included on 26 November 2009 and recruitment was
completed on 30 June 2010.
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Data Collection
The investigators completed standardized electronic case report
forms (eCRFs) at baseline. All forms were sent electronically to the
data management centre where checks for completeness, internal
consistency and accuracy were run. A number of measures were
implemented to ensure data quality, including onsite monitoring
visits of all data in randomly selected centres (1% per annum).
Data quality control happened at face-to-face quality control visits
involving review of source documents supporting the adequacy
and accuracy of data collected on the case report forms. At
baseline data were collected on demographics, medical history,
risk factors and lifestyle, physical condition and vital signs, current
symptoms and treatments. Available results of laboratory tests,
invasive and non-invasive tests were collected, but no test was
mandated by the study and there was no standardized measure-
ment of the left ventricular ejection fraction.
Patient confidentiality was ensured by utilizing patient identi-
fication code numbers to correspond to the computer files. The
study is registered (ISRCTN43070564).
Statistical Analysis
All CLARIFY data are collected and analysed at an indepen-
dent academic statistics centre at the Robertson Centre for
Biostatistics, University of Glasgow, United Kingdom, which is
responsible for the management of the database, all analyses (using
the SAS statistical program, version 9.2 or higher), and storing the
data according to regulations. Baseline characteristics for the
whole population, according to renal function, are presented using
descriptive statistics with mean (standard deviation [SD]) or
median (quartile 1, quartile 3 [Q1, Q3]) for continuous variables,
depending on the distribution of the data, and as counts
(percentages) for categorical data.
We analysed the CLARIFY population at baseline grouped by
eGFR according to the CKD-Epidemiology Collaboration (CKD-
EPI) formula [11] (Table S2). Patients were categorized according
to CKD stage [12]: stage 1, .89 mL/min/1.73 m2; stage 2,
60–89 mL/min/1.73 m2; stage 3a, 45–59 mL/min/1.73 m2; and
stage 3b–5: ,45 mL/min/1.73 m2. CKD-EPI was selected since
data suggest that it may be more accurate than other creatinine-
based formulae when applied to a population of patients in which
a large proportion have eGFR.60 mL/min/1.73 m2 [11]. Patients
with CKD stages 3b, 4 and 5 (eGFR,45 mL/min/1.73 m2) were
grouped since it was anticipated that there would be small numbers
with stages 4 or 5 in particular. The prevalence of renal dysfunction
and the differential characteristics of these patients are described.
Management of these patients is also depicted.
In order to explore medication use further, an analysis of how
many patients received all cardiovascular preventive measures was
performed. Data for each renal function group were analysed
according to the number (%) of patients who received ‘all
secondary preventive measures’, defined as taking at least one
medication from all three of the following drug categories: (i)
antiplatelet, (ii) statin, and (iii) ACE inhibitor or angiotensin
receptor blocker (ARB).
Comparisons between the renal function groups were made
using either one-way analysis of variance or the Kruskal–Wallis
test for continuous data, depending on the distribution of the data,
or the chi-square test for categorical data.
Univariate and multivariable logistic regression analyses were
also performed to ascertain the relationship between renal
dysfunction and management. Analyses were performed to
examine the effect of renal dysfunction on the use of ACE
inhibitors and then separately the use of ARBs. The multivariable
analyses were adjusted for other clinical and demographic
variables known to have a relationship with the use of these
therapies, and included the following: age, body mass index (BMI),
systolic blood pressure, diastolic blood pressure, gender, heart rate,
smoking status, history of heart failure, angina, diabetes mellitus
and hypertension.
Results
Of the 33,432 patients screened, 329 patients were missing
institutional review board approval or consent, 102 did not
provide consent and 46 did not meet the inclusion criteria, leaving
32,955 patients for analysis. Of these, 22,272 patients had all of the
baseline variables available to permit eGFR calculation and
thereby formed the final study group (Figure 1). The mean age was
63.9610.4 years, 77.3% were male, 61.8% had a history of MI,
71.9% had treated hypertension, 30.4% were diabetic, 75.4%
Figure 1. Patient flow chart.
doi:10.1371/journal.pone.0102335.g001
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were dyslipidaemic and 5.0% had a prior hospitalization for
chronic heart failure (Table 1). The majority of patients were white
(74.3%). Just over half of the study population had received PCI
(56.6%) and 24.2% CABG; most (76.0%) were free of symptom-
atic angina.
Table 1 also shows the demographics of patients by eGFR
status. Chronic kidney disease (eGFR,60 mL/min/1.732) was
seen in 22.1%. Patients with lower eGFR were older, with a higher
prevalence of women, comorbidities, cardiovascular risk factors
and overt vascular disease. Patients with CKD were more likely to
have undergone CABG but less likely to have had PCI compared
to those with preserved renal function. The prevalence of atrial
fibrillation/flutter (AF) and chronic heart failure increased in
stepwise fashion whereas the proportion of active smokers
decreased in patients with lower eGFR.
Clinical findings and investigations according to eGFR category
are shown in Table 2. Patients with lower eGFR exhibited higher
systolic blood pressures whilst the converse was seen for diastolic
pressure. There were no clinically meaningful differences in heart
rate or lipid profile. Haemoglobin concentration was progressively
lower according to worse CKD class.
Drug therapy is detailed in Table 3. High use of secondary
prevention was seen across all CKD stages (overall 93.4% for lipid-
lowering drugs, 95.3% antiplatelets, 75.9% beta-blockers). When
considering the whole study population, statins were being taken
by 84.3% of patients; a small but significant stepwise reduction in
use was seen in patients with lower eGFR. Antiplatelet use was
progressively reduced in patients with lower eGFR; the converse
was seen for oral anticoagulant use. When considering patients
with a history of AF, the proportion receiving oral anticoagulation
significantly increased in a step-wise fashion as CKD class
Table 1. Demographic data: characteristics of the study population classified according to eGFR group calculated using the CKD-
EPI.
Variable Total (n=22,272) eGFR (mL/min/1.73 m
2) p-valuea
,45
(n=1,528)
45–59
(n=3,389)
60–89
(n=11,826)
$90
(n=5,529)
Age, mean (SD), years 63.9610.4 71.469.5 69.868.8 64.769.5 56.568.8 ,0.0001
Men, n (%) 17,221 (77.3) 968 (63.4) 2,283 (67.4) 9,331 (78.9) 4,639 (83.9) ,0.0001
BMI, median (Q1, Q3), kg/m2 27.5 (24.9, 30.5) 27.5 (24.7, 30.8) 27.5 (24.9, 30.7) 27.4 (25.0, 30.4) 27.5 (24.9, 30.8) 0.25
Time since 1st CAD diagnosis,
median (Q1, Q3), years
4 (2, 9) 6 (2, 12) 6 (2, 11) 5 (2, 10) 3 (1, 7) ,0.0001
Myocardial infarction, n (%) 13,759 (61.8) 956 (62.6) 2,015 (59.5) 7,255 (61.4) 3,533 (63.9) 0.0002
PCI, n (%) 12,606 (56.6) 755 (49.4) 1,729 (51.0) 6,643 (56.2) 3,479 (62.9) ,0.0001
CABG, n (%) 5,386 (24.2) 462 (30.3) 977 (28.8) 2,901 (24.5) 1,046 (18.9) ,0.0001
Internal cardiac defibrillator, n (%) 284 (1.3) 54 (3.5) 56 (1.7) 132 (1.1) 42 (0.8) ,0.0001
Pacemaker, n (%) 489 (2.2) 88 (5.8) 117 (3.5) 237 (2.0) 47 (0.9) ,0.0001
Stroke, n (%) 951 (4.3) 137 (9.0) 205 (6.0) 484 (4.1) 125 (2.3) ,0.0001
Transient ischaemic attack, n (%) 694 (3.1) 92 (6.0) 178 (5.3) 311 (2.6) 113 (2.0) ,0.0001
Peripheral artery disease, n (%) 2,122 (9.5) 240 (15.7) 420 (12.4) 1,075 (9.1) 387 (7.0) ,0.0001
Hospitalization for CHF, n (%) 1,120 (5.0) 202 (13.2) 237 (7.0) 504 (4.3) 177 (3.2) ,0.0001
Treated hypertension, n (%) 16,000 (71.9) 1,297 (84.9) 2,660 (78.5) 8,423 (71.2) 3,620 (65.5) ,0.0001
Diabetes, n (%) 6,763 (30.4) 688 (45.0) 1,159 (34.2) 3,276 (27.7) 1,640 (29.7) ,0.0001
Dyslipidaemia, n (%) 16,794 (75.4) 1,189 (77.8) 2,542 (75.0) 8,969 (75.9) 4,094 (74.1) 0.009
Atrial fibrillation/flutter, n (%) 1,615 (7.3) 211 (13.8) 384 (11.3) 839 (7.1) 181 (3.3) ,0.0001
Asthma/COPD, n (%) 1,750 (7.9) 156 (10.2) 300 (8.9) 964 (8.2) 330 (6.0) ,0.0001
Smoking status, n (%)
Current 2,828 (12.7) 99 (6.5) 254 (7.5) 1,436 (12.2) 1,039 (18.8)
Former 10,302 (46.3) 669 (43.8) 1,479 (43.6) 5,619 (47.5) 2,535 (45.9)
Never 9,137 (41.0) 760 (49.7) 1,656 (48.9) 4,768 (40.3) 1,953 (35.3)
Angina and CCS class, n (%) ,0.0001
No Angina 1,6921 (76.0) 1,142 (74.7) 2,512 (74.1) 8,961 (75.8) 4,306 (77.9)
CCS class I 1,527 (6.9) 98 (6.4) 222 (6.6) 832 (7.0) 375 (6.8)
CCS class II 2,802 (12.6) 193 (12.6) 498 (14.7) 1,486 (12.6) 625 (11.3)
CCS class III 953 (4.3) 90 (5.9) 151 (4.5) 506 (4.3) 206 (3.7)
CCS class IV 61 (0.3) 5 (0.3) 6 (0.2) 35 (0.3) 15 (0.3)
Abbreviations: CABG, coronary artery bypass graft; CAD, coronary artery disease; CCS, Canadian Cardiovascular Society; CHF, chronic heart failure; CKD-EPI, Chronic
Kidney Disease–Epidemiology Collaboration; COPD, chronic obstructive pulmonary disease; eGFR, estimated glomerular filtration rate; NYHA, New York Heart
Association; PCI, percutaneous coronary intervention; SD, standard deviation.
ap-value tests for differences across eGFR groups.
doi:10.1371/journal.pone.0102335.t001
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deteriorated. The use of calcium channel antagonists, ARBs,
diuretics, digoxin, amiodarone and insulin was increased in those
patients with lower eGFR. ACE inhibitor use was lower and
inversely related to lower eGFR. A similar pattern of use was seen
for patients (n = 13,759) with a history of MI (data not shown).
In the overall study population, 62.6% received all three
secondary prevention treatments (antiplatelet plus statin plus ACE
or ARB), with a significant reduction seen with lower eGFR
(Table 3).
We explored the relationship between renal function and the
use of ACE/ARB further (Figures 2 and 3). Univariate analysis
demonstrated that renal function (eGFR) was a significant and
independent predictor for both ACE inhibitor and ARB use when
considered as a continuous (data not shown) or categorical
variable; lower eGFR values had reduced odds of ACE inhibitor
use, whereas the converse was seen for ARB use. These
associations were consistent following adjustment for a number
of variables (age, body mass index, systolic blood pressure, diastolic
blood pressure, gender, heart rate, smoking status, history of heart
failure, angina, diabetes and hypertension). The odds of taking
ACE inhibitors in the severely impaired renal function group were
0.75 (95% confidence interval [CI] 0.67, 0.84) compared to those
with eGFR 60–89 mL/min/1.73 m2, whilst the odds of taking
ARBs for the same group were 1.33 (95% CI 1.18, 1.49) compared
to those with renal function 60–89 mL/min/1.73 m2. Patients
with eGFR.90 mL/min/1.73 m2 had very similar results to
those in the 60–89 mL/min/1.73 m2 group.
Discussion
Published data on the prevalence of CKD in patients with stable
CAD are scarce. The CLARIFY study population represents a
unique, contemporary, global cohort of patients with stable CAD.
In our study, where 22,272 patients were included, CKD (defined
as eGFR ,60 mL/min/1.73 m2) is seen in just under one-quarter
of patients with CAD and is associated with increasing age, female
sex, cardiovascular risk factors, overt vascular disease, other
comorbidities, and higher systolic but lower diastolic blood
pressure. Severe CKD (eGFR,45 mL/min/1.73 m2), which has
previously been shown to be associated with poor prognosis, is as
common as AF (6.9% and 7.3%, respectively).
Table 3. Drug treatment for all patients with available data according to eGFR group calculated using the CKD-EPI.
Variable Total (n=22,272) eGFR (mL/min/1.73 m
2) p-valuea
,45 (n=1,570) 45–59 (n=3,443) 60–89 (n=11,958) $90 (n=5,589)
Antiplatelet, n (%) 21,228 (95.3) 1,385 (90.6) 3,152 (93.0) 11,288 (95.5) 5,403 (97.7) ,0.0001
Aspirin, n (%) 19,876 (89.3) 1,238 (81.1) 2,900 (85.6) 10,578 (89.5) 5,160 (93.4) ,0.0001
Thienopyridine, n (%) 5,707 (25.7) 404 (26.5) 797 (23.6) 2,872 (24.3) 1,634 (29.6) ,0.0001
Other antiplatelet, n (%) 2,067 (9.3) 153 (10.0) 299 (8.8) 1,050 (8.9) 565 (10.2) 0.02
Oral anticoagulant, n (%) 1,734 (7.8) 205 (13.5) 353 (10.4) 890 (7.5) 286 (5.2) ,0.0001
Oral anticoagulants in AFb, n (%) 753 (43.9) 110 (51.2) 192 (46.5) 374 (42.4) 77 (37.7) 0.02
Neither antiplatelet nor oral
anticoagulant, n (%)
399 (1.8) 35 (2.3) 81 (2.4) 216 (1.8) 67 (1.2) 0.0002
Beta-blocker, n (%) 16,906 (75.9) 1,160 (75.9) 2548 (75.2) 8,861 (74.9) 4,337 (78.5) ,0.0001
Ivabradine, n (%) 2,177 (9.8) 150 (9.8) 362 (10.7) 1,162 (9.8) 503 (9.1) 0.11
Calcium antagonist, n (%) 6,069 (27.3) 513 (33.6) 1,076 (31.7) 3,204 (27.1) 1,276 (23.1) ,0.0001
Verapamil or diltiazem, n (%) 1,287 (5.8) 86 (5.6) 196 (5.8) 720 (6.1) 285 (5.2) 0.11
Dihydropyridine, n (%) 4,827 (21.7) 431 (28.2) 884 (26.1) 2,509 (21.2) 1,003 (18.1) ,0.0001
ACE inhibitor, n (%) 11,586 (52.0) 676 (44.2) 1,715 (50.6) 6,190 (52.3) 3,005 (54.4) ,0.0001
ARB, n (%) 5,951 (26.7) 570 (37.3) 1,086 (32.1) 3,086 (26.1) 1,209 (21.9) ,0.0001
Neither ACE nor ARB, n (%) 5,169 (23.2) 342 (22.4) 674 (19.9) 2,763 (23.4) 1,390 (25.1) ,0.0001
Lipid lowering, n (%) 20,791 (93.4) 1,412 (92.4) 3,110 (91.8) 11,054 (93.5) 5,215 (94.3) ,0.0001
Statin, n (%) 18,776 (84.3) 1,251 (81.9) 2,783 (82.1) 10,033 (84.8) 4,709 (85.2) ,0.0001
Diuretic, n (%) 6,614 (29.7) 836 (54.7) 1,399 (41.3) 3233 (27.3) 1,146 (20.7) ,0.0001
Other antihypertensive drug, n (%) 1,660 (7.5) 245 (16.0) 303 (8.9) 790 (6.7) 322 (5.8) ,0.0001
Digoxin and derivatives, n (%) 599 (2.7) 94 (6.2) 141 (4.2) 279 (2.4) 85 (1.5) ,0.0001
Amiodarone/dronedarone, n (%) 632 (2.8) 90 (5.9) 179 (5.3) 289 (2.4) 74 (1.3) ,0.0001
NSAID, n (%) 1,186 (5.3) 94 (6.2) 217 (6.4) 659 (5.6) 216 (3.9) ,0.0001
Insulin, n (%) 1,533 (6.9) 245 (16.0) 283 (8.4) 656 (5.5) 349 (6.3) ,0.0001
Oral antidiabetic agent, n (%) 4,833 (21.7) 425 (27.8) 813 (24.0) 2,364 (20.0) 1,231 (22.3) ,0.0001
All secondary preventive measures,
n (%)
13,936 (62.6) 893 (58.4) 2,110 (62.3) 7,465 (63.1) 3,468 (62.7) 0.0049
Abbreviations: ACE, angiotensin converting enzyme; AF, atrial fibrillation; ARB, angiotensin receptor blocker; CKD-EPI, Chronic Kidney Disease–Epidemiology
Collaboration; eGFR, estimated glomerular filtration rate; NSAID, non-steroidal anti-inflammatory drug.
ap-value tests for differences across eGFR groups.
bFor patients with history of (or currently in) AF.
doi:10.1371/journal.pone.0102335.t003
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Compared with recent published data, the prevalence of
CKD in patients with CAD is greater than that seen in the
general population. For example, contemporary data from a
representative sample of the Canadian general population
demonstrated a prevalence of CKD (any stage) of 12.5% [13].
The estimated prevalence of patients with CKD stages 3–5
(eGFR,59 mL/min/1.73 m2) was 3.1%, increasing to 18.6%
when considering only subjects .65 years of age. The latter figure
is perhaps more relevant, since the mean age of subjects in our
study was 64 years. A recent study of consecutive patients
receiving primary PCI for myocardial infarction in the UK
demonstrated a mean age of approximately 64 years, with 17.6%
exhibiting CKD stages 3–5 [14]. In the Canadian study [13], the
prevalence of comorbidities such as hypertension and diabetes
mellitus was greater in those with CKD, but no real difference in
lipid profile (excepting triglycerides) was seen. A similar finding in
relation to lipid profile was seen in our population, where no
meaningful clinical difference in lipids levels was seen across the
CKD stages. The United States National Health and Nutrition
Examination Survey dataset show a total crude CKD prevalence
estimate for adults aged $20 years to be 16.8%, of which 5.4%
were in CKD stage 3 and 0.4% in stages 4 or 5 [15]. The
prevalence of renal disease was significantly associated with age.
The finding that almost one-quarter of subjects in the current
study had CKD is likely to be explained in part by age but also by
the high presence of comorbidities in patients with CAD, when
compared with the general unselected population. For example,
when considering all subjects, 30.4% had a history of diabetes
mellitus, 71.9% treated hypertension, 75.4% dyslipidaemia and
61.8% prior myocardial infarction. Patients with severe CKD
demonstrated a significantly higher prevalence of diabetes mellitus
(45.0%) and hypertension (84.9%). Female sex was associated with
lower eGFR; this relationship is likely to be influenced by
increasing age and is in keeping with previous studies of patients
with CAD [1].
It is not possible from the current study to determine if the
presence of comorbid conditions led to the development of
concomitant CAD and CKD (i.e. shared aetiological risk) or
whether when present they contribute to accelerated decline in
renal function. Alternatively renal impairment per se may
contribute to adverse risk factor profile, such as hypertension.
For example, the finding that wider pulse pressure, a marker of
increased vascular stiffness [16], was more apparent in subjects
with CKD could lead to the conclusion that it may underlie (at
least in part) the renal dysfunction; yet it is equally plausible that it
might be secondary to it (or perhaps both). It is hoped that the
prospective nature of the CLARIFY study, with annual data
collection, may help to tease out some of these complex
relationships in more detail.
Secondary prevention was generally very good across all
categories of renal function with no meaningful differences in
use of beta-blockers. This is a major difference when the current
data are compared with historical datasets, most of which were
obtained in an acute or subacute care setting [8,17–19]. These
findings were consistent across subgroups of patients, such as those
with a history of MI or CABG. A small but significant stepwise
reduction in statin use was seen in patients with lower eGFR.
Antiplatelet therapy use declined with lower eGFR; this may be
explained by the concomitant increase in use of anticoagulant
therapy and higher prevalence of AF with impaired renal function.
To try to identify any gap in implementation of secondary
prevention in clinical practice, we assessed the number of patients
within each renal function group who were taking evidence-based
therapy in the form of an antiplatelet, a statin, and an ACE
inhibitor or ARB. Just under two-thirds (62.6%) of the patients
were found to be on this combination of drugs and a significant
reduction was seen in patients with CKD (e.g. 58.4% in patients
with CKD stage 3b–5). It is possible that the appropriate
utilization of anticoagulant therapy for patients with AF may
have influenced use of antiplatelet therapy.
Just over three-quarters (76.8%) of the overall patient group
received either an ACE inhibitor or ARB (or both), and this order
of magnitude was even seen when considering patients with severe
CKD (stages 3b–5, 77.6%). However, ACE inhibitors were not
used in a similar proportion across the eGFR groups; a step-wise
reduction in use was seen in patients with lower eGFR. The
opposite was seen for ARBs. These findings were independent of a
number of clinical variables that might impact on use of these
drugs, including history of hypertension, diabetes and age. A
similar trend of higher use of ARBs following PCI for ST-elevation
MI was seen in patients with severe CKD in a recently published
UK study [14]. Guidelines relating to the management of patients
with CKD do not differentiate between the use of ACE inhibitors
or ARBs [20]. Further evaluation is required to fully understand
these associations.
When considering patients with a history of AF, the proportion
receiving oral anticoagulation significantly increased in step-wise
fashion as CKD class deteriorated (37.8% amongst patients with
CKD stage 1 to 51.2% in stages 3b–5). Renal impairment has
recently been shown to be associated with higher risk of stroke and
peripheral embolism in patients with AF [21].
Significant differences in the rates of use of other drug classes
were seen across CKD stages. For example, dihydropyridine
calcium channel blockers, diuretics, other antihypertensive drugs,
digoxin and amiodarone were more frequently prescribed in
patients with lower eGFR, most likely reflecting the associated
high prevalence of comorbidities, including hypertension and AF.
This study has a number of limitations. For example, there are
no data available with respect to albuminuria, and data on left
ventricular function (e.g. from echocardiogram) were not system-
atically required for the study. The current study population
comprises 68% of the total CLARIFY population, due to
insufficient baseline data being available in the remainder. In
some countries ethnicity data were not collected due to legal or
ethical reasons (hence eGFR could not be calculated) and not all
subjects had recent local laboratory data available (not mandated
for the study). Whilst CKD per se was not an exclusion criterion, it
is plausible that subjects with more severely impaired renal
function may have been excluded on the basis of this being
considered as hampering the collection of 5-year follow-up data.
Renal function has been analysed according to eGFR, which is
derived from a single serum creatinine assessment. This might lead
to an overestimate of the prevalence of CKD stages 3–5. Whilst
most western laboratories use a creatinine method that has
calibration traceable to an isotope dilution mass spectrometry
reference measurement procedure, given the international scope of
this collaborative study it was difficult to establish the creatinine
validation technique for all laboratories. It is plausible that this
may have led to some error in attribution of diagnosis of CKD, but
which was unavoidable. We chose to use CKD-EPI, as it performs
Figure 2. Univariate relationship between chronic kidney disease class and use of (A) angiotensin-converting enzyme inhibitors
and (B) angiotensin receptor blocker.
doi:10.1371/journal.pone.0102335.g002
CKD and Stable Coronary Artery Disease
PLOS ONE | www.plosone.org 8 July 2014 | Volume 9 | Issue 7 | e102335
CKD and Stable Coronary Artery Disease
PLOS ONE | www.plosone.org 9 July 2014 | Volume 9 | Issue 7 | e102335
better at higher GFRs, and data suggest that it may provide
enhanced cardiovascular risk prediction compared with the
Modification of Diet in Renal Disease (MDRD) method [21]. It
is acknowledged that in clinical practice, decision-making regard-
ing medical treatment by the responsible clinician is most likely to
be influenced by serum creatinine and/or eGFR (e.g. in several
countries MDRD-derived eGFR is routinely reported by labora-
tories). We believe that these potential limitations are overcome by
the large size of the described cohort and the fact that the key
findings are consistent irrespective of the method used to analyse
renal function (in general qualitatively similar results with the
MDRD formula [data not shown]). The data presented relate to
‘current treatments’ (i.e. those being taken when the patients were
assessed at baseline). Owing to the nature of an observation study,
it is not possible to ascertain whether patients were actually taking
their prescribed medications.
In summary, baseline data from the CLARIFY study show that
CKD is common in patients with stable CAD and is associated
with age and comorbidities. Secondary prevention on the whole
appears to be good, with high use of antiplatelet agents, statins,
and beta-blockers. Around three-quarters of patients were
prescribed either an ACE inhibitor or ARB, irrespective of renal
function. In patients with severe CKD, there is lower use of ACE
inhibitors, whereas ARBs are increasingly used. Yet the study
shows opportunities for improvement in terms of increasing the
proportion of patients taking all three evidence-based therapies for
cardiovascular prevention. Many questions regarding the relation-
ship between CKD and CVD remain unanswered. We believe
that prospective data from the CLARIFY study will, in due course,
help shed further light on this by permitting evaluation of the
association of renal function on cardiovascular outcomes and
mortality. The study will also assess the prognostic importance of
and predictors for change in renal function over time.
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